
AXP · NYSE
The supplied consensus is Buy across 27 analysts, but its target figures are internally inconsistent: it reports a $320 low and $320 high alongside a $365 mean, so they cannot establish a valid target range or spread. Separate snapshots cite averages of $365.19 at MarketBeat, $372.47 at TipRanks, and $385.12 at ChartMill, but they do not provide a comparable analyst set or individual highest and lowest targets. Stockanalysis reports Evercore ISI raising its target to $330 from $320 with an In Line rating, and Citi’s Benjamin Gerlinger lowering his to $335 from $340 with a Neutral rating; the snippet gives no action dates, so their timing within the week is unclear. The disagreement centers on premium spending, fees, and the raised outlook versus soft commercial growth, benefit costs, and credit risk.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| UBS | — | $345 | +5.9% | Oct 5, 2026 | Open the report this row came from | |
| Morgan Stanley | — | $382 | +17.2% | Jul 27, 2026 | Open the report this row came from |